Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Enhanced Expression of Podoplanin in Oral Carcinomas in situ and Squamous Cell Carcinomas

Funayama A.a, b · Cheng J.a · Maruyama S.c · Yamazaki M.a · Kobayashi T.c · Syafriadi M.a · Kundu S.a · Shingaki S.b · Saito C.b · Saku T.a, c

Author affiliations

Divisions of aOral Pathology and bReconstructive Surgery for the Oral and Maxillofacial Region, Department of Tissue Regeneration and Reconstruction, Niigata University Graduate School of Medical and Dental Sciences, and cOral Pathology Section, Department of Surgical Pathology, Niigata University Hospital, Niigata, Japan

Corresponding Author

Prof. Takashi Saku

Division of Oral Pathology, Department of Tissue Regeneration and Reconstruction

Niigata University Graduate School of Medical and Dental Sciences

2-5274 Gakkocho-dori, Chuo-ku, Niigata 951-8514 (Japan)

Tel. +81 25 227 2832, E-Mail tsaku@dent.niigata-u.ac.jp

Related Articles for ""

Pathobiology 2011;78:171–180

Do you have an account?

Login Information

Contact Information

By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.

I have read the Karger Terms and Conditions and agree.


Objective: Podoplanin, a known lymphatic endothelial cell marker, has been reported to be expressed in various types of cancer. To elucidate the expression of podoplanin in precancerous lesions, we examined the immunohistochemical profiles of podoplanin in oral squamous epithelial lesions. Method: We studied a total of 298 foci of squamous cell carcinoma (SCC), carcinoma in situ (CIS), epithelial dysplasia, and hyperplastic and/or normal epithelial lesions by immunohistochemistry using D2-40. Results: There was no positivity for podoplanin in normal or hyperplastic epithelia, while all of the CIS and SCC foci stained positive. Approximately one third of the mild dysplasia foci (10 of 36 foci, 28%) and 80% of moderate dysplasia foci (78/98) showed grade 1 positive reactions (positive only in the 1st layer). Grade 2 reactions (up to 4th layer) were seen in 4 of 98 moderate dysplasia foci (4%), 29 of 74 CIS foci (39%), and 3 of 30 SCC foci (10%). Grade 3 reactions (to more than 5th layer) were found in 35 (47%) CIS foci and 26 (87%) SCC foci. Conclusions: The relationship between the present histological categorization and podoplanin grade was statistically significant. D2-40 expression is considered to be related to the severity of oral precancerous lesions.

© 2011 S. Karger AG, Basel


  1. Franceschi S, Bodoli E, Herrero R, Muñoz N: Comparison of cancers of the oral cavity and pharynx worldwide: etiological clues. Oral Oncol 2000;36:106–115.
  2. Statistic and Information Department, the Minister’s Secretariat, Ministry of Health, Labour and Welfare, Japan, Health and Welfare Statistics Association: Vital Statistics of Japan 2006. Tokyo, Yamatosogo Publishing, 2006, pp 270–275.
  3. Gale N, Piclch BZ, Sidransky D, El Naggar A, Westra W, Califano J, Johnson N, MacDonald DG: Epithelial precursor lesions; in Barnes L, Evson JW, Reichart P, Sidransky D (eds): Pathology and Genetics of Head and Neck Tumours. World Health Organization Classification of Tumours. Lyon, IARC Press, 2005, pp 177–179.
  4. Pindborg JJ, Reichart PA, Smith CJ, van der Waal I: Squamous epithelial dysplasia: Histological typing of cancer and precancer of the oral mucosa; in Pindborg JJ, Reichart PA, Smith CJ, van der Waal I (eds): World Health Organization International Histological Classification of Tumours. Berlin, Springer, 1997, pp 24–26.
  5. Wahi PN, Cohen B, Luthra UK, Torloni H: Histological typing of oral and oropharyngeal tumours; in Wahi PN, Cohen B, Luthra UK, Torloni H (eds): International Histological Classification of Tumours. Geneva, World Health Organization, 1971, pp 19, 23.
  6. Kobayashi T, Maruyama S, Cheng J, Ida-Yonemochi H, Yagi M, Takagi R, Saku T: Histopathological varieties of oral carcinoma in situ: diagnosis aided by immunohistochemistry dealing with the second basal cell layer as the proliferating center of oral mucosal epithelia. Pathol Int 2010;60:156–166.
  7. Takeda T, Sugihara K, Hirayama Y, Hirano M, Tanuma JI, Semba I: Immunohistological evaluation of Ki-67, p63, CK19 and p53 expression in oral epithelial dysplasias. J Oral Pathol Med 2006;35:369–375.
  8. Eriksen JG, Steiniche T, Søgaard H, Overgaard J: Expression of integrins and E-cadherin in squamous cell carcinomas of the head and neck. APMIS 2004;112:560–568.
  9. Alvarado CG, Maruyama S, Cheng J, Ida-Yonemochi H, Kobayashi T, Yamazaki M, Takagi R, Saku T: Nuclear translocation of β-catenin synchronized with loss of E-cadherin in oral epithelial dysplasia with a characteristic two-phase appearance. Histopathology, in press.
  10. Ikarashi T, Ida-Yonemochi H, Ohshiro K, Cheng J, Saku T: Intraepithelial expression of perlecan, a basement membrane-type heparan sulfate proteoglycan reflects dysplastic changes of the oral mucosal epithelium. J Oral Pathol Med 2004;33:87–95.
  11. Tilakaratne WM, Kobayashi T, Ida-Yonemochi H, Swelam W, Yamazaki M, Mikami T, Alvarado CG, Shahidul AM, Maruyama S, Cheng J, Saku T: Matrix metalloproteinase 7 and perlecan in oral epithelial dysplasia and carcinoma in situ: an aid for histopathologic recognition of their cell proliferation centers. J Oral Pathol Med 2009;38:348–355.
  12. Marks A, Sutherland DR, Bailey D, Iglesias J, Law J, Lei M, Yeger H, Banerjee D, Baumal R: Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 1999;80:569–578.
  13. Evangelou E, Kyzas PA, Trikalinos TA: Comparison of the diagnostic accuracy of lymphatic endothelium markers: Bayesian approach. Mod Pathol 2005;18:1490–1497.
  14. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999;154:385–394.
  15. Saad RS, Kordunsky L, Liu YL, Denning KL, Kandil HA, Silverman JF: Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol 2006;19:1317–1323.
  16. Kundu S, Cheng J, Maruyama S, Suzuki M, Kawashima H, Saku T: Lymphatic involvement in the histopathogenesis of mucous retention cyst. Pathol Res Pract 2007;203:89–97.
  17. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005;166:913–921.
  18. Dumoff KL, Chu C, Xu X, Pasha T, Zhang PJ, Acs G: Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Mod Pathol 2005;18:97–104.
  19. Dumoff KL, Chu CS, Harris EE, Holtz D, Xu X, Zhang PJ, Acs G: Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation. Mod Pathol 2006;19:708–716.
  20. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J, Quintanilla M: Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 2005;113:899–910.
  21. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, Mao L: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006;107:563–569.
  22. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L: Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008;26:354–360.
  23. Syafriadi M, Cheng J, Jen KY, Ida-Yonemochi H, Suzuki M, Saku T: Two-phase appearance of oral epithelial dysplasia resulting from focal proliferation of parabasal cells and apoptosis of prickle cells. J Oral Pathol Med 2005;34:140–149.
  24. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M: Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol 2005;26:195–200.
  25. Gandarillas A, Scholl FG, Benito N, Gamalllo C, Quintanilla M: Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Mol Carcinog 1997;20:10–18.
  26. Martin-Villar E, Megías D, Castel S, Yurrita MM, Vilaró S, Quintanilla M: Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 2006;119:4541–4553.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: November 11, 2010
Accepted: February 08, 2011
Published online: May 26, 2011
Issue release date: June 2011

Number of Print Pages: 10
Number of Figures: 4
Number of Tables: 1

ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)

For additional information: https://www.karger.com/PAT

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.